Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 6Fallopian Tube Neoplasms 6Breast Neoplasms 6Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Brain Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Rectal Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

AZD 6244 3pirfenidone 2tipifarnib 1cediranib 1Surveys and Questionnaires 1Sorafenib 1Pharmacokinetics 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurofibroma, Plexiform × cediranib × Clear all
NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

National Cancer Institute (NCI)

Phase 2 Terminated
26 enrolled 8 charts
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡